In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, Myriad Genetics, Inc. reported revenue of $190.7 million, down 10.5% from the same quarter a year earlier. It recorded a net loss of $43.2 million. The operating loss came to $38.9 million, an operating margin of -20.4%. Diluted earnings per share were -$0.46.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
807
-3.2%
|
191
-10.5%
|
200
+2.3%
|
210
-0.4%
|
206
-3.6%
|
213
+0.8%
|
196
-3.1%
|
211
+7.1%
|
213
+11.2%
|
| Cost of revenue |
251
+2.1%
|
64
+3.9%
|
63
+1.8%
|
63
+5.5%
|
62
-2.5%
|
61
-4.8%
|
62
-4.5%
|
60
|
64
+10.2%
|
| Gross profit |
555
-5.4%
|
127
-16.3%
|
138
+2.5%
|
147
-2.7%
|
144
-4.0%
|
152
+3.2%
|
134
-2.5%
|
151
|
150
+11.5%
|
| Research and development |
106
-7.0%
|
25
-2.3%
|
27
-1.5%
|
26
-20.8%
|
28
-1.1%
|
26
-5.5%
|
28
+10.4%
|
32
+53.3%
|
28
+18.8%
|
| Selling, general and administrative |
540
|
141
+1.6%
|
136
+0.1%
|
124
|
139
-0.1%
|
139
-4.3%
|
136
-3.5%
|
—
|
139
+2.2%
|
| Operating expenses |
—
|
166
|
—
|
—
|
167
|
—
|
163
-1.4%
|
—
|
—
|
| Operating income |
-99
+76.4%
|
-39
+88.2%
|
-31
-5.9%
|
-6
+85.4%
|
-23
-16.5%
|
-329
-801.9%
|
-29
-3.9%
|
-39
-24.2%
|
-20
+66.7%
|
| Interest income |
2
+100.0%
|
0
+100.0%
|
1
+133.3%
|
1
+166.7%
|
0
+25.0%
|
0
-50.0%
|
0
-50.0%
|
0
-57.1%
|
0
-33.3%
|
| Interest expense |
16
+331.6%
|
4
+173.3%
|
4
+412.5%
|
4
+528.6%
|
4
+375.0%
|
2
+87.5%
|
1
|
1
|
1
|
| Other non-operating income (expense) |
1
+260.0%
|
0
+100.0%
|
0
-100.0%
|
0
+33.3%
|
0
+150.0%
|
-0
+66.7%
|
0
-94.7%
|
0
+142.9%
|
-1
-14.3%
|
| Pretax income |
-112
+73.4%
|
-43
+87.1%
|
-34
-16.0%
|
-9
+77.2%
|
-26
-23.6%
|
-331
-788.7%
|
-29
-13.5%
|
-39
-21.1%
|
-21
+65.4%
|
| Income tax |
1
+103.2%
|
1
+700.0%
|
0
+100.0%
|
-1
-129.4%
|
1
+33.3%
|
-0
+80.0%
|
-29
-29400.0%
|
3
+409.1%
|
1
+800.0%
|
| Net income |
-113
+71.5%
|
-43
+86.9%
|
-34
-34000.0%
|
-8
+81.4%
|
-27
-24.0%
|
-330
-800.5%
|
-0
+99.6%
|
-42
-36.2%
|
-22
+63.9%
|
| Basic EPS |
-1.20
+72.2%
|
-0.46
+87.1%
|
-0.36
|
-0.08
+81.9%
|
-0.29
-20.8%
|
-3.57
-770.7%
|
0.00
+100.0%
|
-0.47
-29.4%
|
-0.24
+68.0%
|
| Diluted EPS |
-1.20
+72.2%
|
-0.46
+87.1%
|
-0.36
|
-0.08
+81.9%
|
-0.29
-20.8%
|
-3.57
-770.7%
|
0.00
+100.0%
|
-0.47
-29.4%
|
-0.24
+68.0%
|
| Weighted average shares, basic |
94
+2.5%
|
95
+2.5%
|
94
+2.5%
|
93
+2.8%
|
93
+2.4%
|
92
+2.1%
|
91
+1.7%
|
91
+5.3%
|
91
+11.0%
|
| Weighted average shares, diluted |
94
+2.5%
|
95
+2.5%
|
94
+2.5%
|
93
+2.8%
|
93
+2.4%
|
92
+2.1%
|
91
+1.7%
|
91
+5.3%
|
91
+11.0%
|
| Other measures | |||||||||
| Depreciation and amortization |
50
-14.8%
|
12
-11.3%
|
12
-13.2%
|
13
-14.9%
|
13
-19.2%
|
14
-6.6%
|
14
-8.3%
|
15
-2.0%
|
16
+10.6%
|
| EBITDA |
-48
+86.5%
|
-26
+91.6%
|
-18
-24.7%
|
7
+128.5%
|
-11
-143.2%
|
-315
-1372.4%
|
-15
-19.7%
|
-24
-48.5%
|
-4
+90.4%
|
| Interest coverage |
-6.01x
|
-9.49x
|
-7.49x
|
-1.30x
|
-6.13x
|
-219.47x
|
-36.25x
|
-55.71x
|
-25.00x
|
| Margins | |||||||||
| Gross margin |
68.83%
|
66.60%
|
68.66%
|
69.97%
|
69.91%
|
71.23%
|
68.50%
|
71.65%
|
70.23%
|
| Operating margin |
-12.22%
|
-20.40%
|
-15.32%
|
-2.72%
|
-11.33%
|
-154.48%
|
-14.80%
|
-18.52%
|
-9.38%
|
| Pretax margin |
-13.86%
|
-22.34%
|
-17.02%
|
-4.24%
|
-12.74%
|
-155.14%
|
-15.01%
|
-18.57%
|
-9.94%
|
| Profit margin |
-13.96%
|
-22.65%
|
-17.02%
|
-3.77%
|
-13.32%
|
-155.09%
|
-0.05%
|
-20.18%
|
-10.36%
|
| EBITDA margin |
-6.00%
|
-13.84%
|
-9.08%
|
3.29%
|
-5.20%
|
-147.86%
|
-7.45%
|
-11.49%
|
-2.06%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- MYGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Accelerated filer
- SEC CIK
- 899923
- Former names
- MYRIAD GENETICS INC (until Nov 5, 2026)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.